about
CD30: from basic research to cancer therapyMacrophages present exogenous antigens by class I major histocompatibility complex molecules via a secretory pathway as a consequence of interferon-gamma activationSerious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.Phenotypic characterization of subsets of T cell lymphoma: towards a functional classification of T cell lymphoma.Deciphering CD30 ligand biology and its role in humoral immunity.Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
CD30 prevents T-cell responses to non-lymphoid tissues.
@ast
CD30 prevents T-cell responses to non-lymphoid tissues.
@en
type
label
CD30 prevents T-cell responses to non-lymphoid tissues.
@ast
CD30 prevents T-cell responses to non-lymphoid tissues.
@en
prefLabel
CD30 prevents T-cell responses to non-lymphoid tissues.
@ast
CD30 prevents T-cell responses to non-lymphoid tissues.
@en
P2093
P2860
P1476
CD30 prevents T-cell responses to non-lymphoid tissues.
@en
P2093
P2860
P356
10.1111/J.1600-065X.1999.TB01303.X
P577
1999-06-01T00:00:00Z